DDInter1094 DDInter782
Lorlatinib is a third-generation ALK tyrosine kinase inhibitor (TKI) for patients with ALK-positive metastatic non-small cell lung cancer which was first approved by the US FDA in November of 2018. It was subsequently approved by the EMA in 2019 for the treatment of select patients with previously treated advanced ALK-positive non-small cell lung cancer, followed by an expanded approval in 2022 to include lorlatinib as a first-line treatment option in advanced ALK-positive NSCLC.
In April 2018, the U.S. Food and Drug Administration (FDA) and the Swiss company Helsinn approved the intravenous formulation of AKYNZEO® (NEPA, a fixed antiemetic combination of fosnetupitant, 235mg, and palonosetron, 0.25mg) as an alternative treatment option for patients experiencing chemotherapy-induced nausea and vomiting . Fosnetupitant is the pro-drug form of netupitant [FDA label]. Generally, 25% to 30% of patients with a diagnosis of cancer receive chemotherapy as a treatment modality and 70% to 80% of these patients undergoing chemotherapy treatment may experience nausea and vomiting as major side effects. Considered one of the most distressing side effects of chemotherapy, nausea and vomiting has an immense impact on the quality of life of patients receiving certain antineoplastic therapies .
Lorlatinib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Lidocaine
Lorlatinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Acetohexamide
Lorlatinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Betrixaban
Lorlatinib {u} may lead to a major life threatening interaction when taken with {v} Venetoclax
Lorlatinib {u} may lead to a major life threatening interaction when taken with {v} Lurbinectedin
Lorlatinib may cause a minor interaction that can limit clinical effects when taken with Lidocaine
Lorlatinib may cause a moderate interaction that could exacerbate diseases when taken with Acetohexamide
Lorlatinib may cause a moderate interaction that could exacerbate diseases when taken with Betrixaban
Lorlatinib may lead to a major life threatening interaction when taken with Venetoclax
Lorlatinib may lead to a major life threatening interaction when taken with Lurbinectedin